Welcome to our dedicated page for STANDARD BIOTOOLS SEC filings (Ticker: LAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Standard BioTools Inc. filings document the regulatory record for a life-science research tools company centered on mass cytometry, microfluidics, genomics, single-cell proteomics and spatial proteomics. Current reports cover operating results, revenue outlook disclosures, restructuring and cost-savings actions, capital-structure changes, material agreements and risk factors tied to its research-use instrument, consumable and service portfolio.
Proxy materials describe board elections, executive compensation votes, auditor ratification, equity incentive plan approvals and employee stock purchase plan amendments. Form 8-K filings also record material events such as the completed SomaLogic sale, related financial disclosures, shareholder voting matters and Nasdaq continued-listing compliance notices.
Standard BioTools Inc. entered into a Termination, Waiver and Release Agreement with Illumina, Inc. under which it received approximately $30 million in cash in exchange for waiving its rights to the 2026 Illumina earnout and terminating related royalty and license agreements tied to SOMAmer-based products. This amount will be included in Standard BioTools’ pro forma net cash position used in the exchange ratio for its pending merger with Treeline Biosciences.
Separately, Standard BioTools signed a Share and Asset Purchase Agreement to sell its Mass Cytometry business to Multiplex Bio Inc. for up to $10 million, consisting of a $5 million seller’s note bearing 6% annual interest, maturing five years after closing, plus a potential $5 million milestone tied to a qualifying sale within ten years. The company may provide Multiplex Bio a working capital loan of up to $10 million if external financing is not obtained. The transaction is subject to stockholder approval, completion of the Treeline merger, customary conditions, an outside date of June 30, 2027 (with possible extensions), and includes a $1 million termination fee and capped expense reimbursements.
STANDARD BIOTOOLS INC. Chief Financial Officer Kim Hanjoon Alex reported a tax-withholding disposition of 202,476 shares of common stock on July 23, 2026, at $0.895 per share to satisfy tax obligations from vested restricted stock units. After this, he directly owned 2,563,054 shares, including 5,000 shares acquired on May 29, 2026 under the Employee Stock Purchase Plan.
Standard BioTools Inc. reported that Nasdaq’s Listing Qualifications Department notified the company on July 22, 2026 that its common stock no longer meets the $1.00 per share Minimum Bid Price Requirement for continued listing on the Nasdaq Global Select Market, after trading below that level for 30 consecutive business days.
The company has 180 calendar days, until January 19, 2027, to regain compliance by maintaining a closing bid price at or above $1.00 for at least 10 consecutive business days. Trading of the LAB common stock continues uninterrupted and business operations and SEC reporting are unaffected. Standard BioTools may seek an additional 180-day period by transferring to the Nasdaq Capital Market and meeting other listing standards, and it is working toward restoring compliance, though there is no assurance it will succeed or receive any extension.
Standard BioTools Inc. filed a Form S-4 registration statement related to its previously announced all-stock merger with Treeline Biosciences. The combined company is expected to be named Treeline Biosciences Holdings, Inc. and to trade on Nasdaq under the ticker “TRLN”, with closing anticipated in the second half of 2026.
At closing, the combined company is expected to have more than $900 million in pro-forma cash, which is expected to fund operations and Treeline’s development pipeline into 2029. Treeline has previously raised approximately $1.2 billion from life sciences investors.
The filing highlights initial Phase 1 dose-escalation data for TLN-121 in relapsed or refractory lymphomas, showing an overall response rate of 84% (16/19) and complete response rate of 32% (6/19), with no observed dose-limiting toxicities as of March 6, 2026. Interim data readouts for TLN-121 and TLN-372 are planned for 2027. The announcement also notes the appointment of Sue Desmond-Hellmann to Treeline’s Board of Directors.
Standard BioTools Inc. plans an all-stock merger with Treeline Biosciences, Inc., valuing Treeline at $2.5 billion and Standard BioTools at $460 million, subject to Parent Net Cash adjustments. Treeline holders are currently estimated to receive about 11.6997 LAB shares per Treeline share, with former Treeline and Standard BioTools stockholders expected to own roughly 84% and 16% of the combined company on a fully diluted basis.
At closing, the company will be renamed Treeline Biosciences Holdings, Inc. and effect a reverse stock split, and expects its stock to trade on Nasdaq as “TRLN”. Each existing LAB share is expected to receive one contingent value right (CVR), collectively allowing issuance of up to 76,000,000 shares over five years from monetizing the mass cytometry and microfluidics “Legacy Business,” certain investments and earnouts, and any surplus Parent Net Cash. Standard BioTools must pursue sale or wind-down of the Legacy Business.
The S-4 also covers resale of shares received by Treeline stockholders; Standard BioTools will not receive proceeds from these resales. A $16.1 million termination fee and up to $5 million expense reimbursement may be payable in specified break scenarios. Voting agreements cover about 39% of LAB shares, and major Treeline holders and directors are subject to 180‑day lock‑ups.
STANDARD BIOTOOLS INC. director Carey Thomas D. reported equity compensation grants consisting of restricted stock units and stock options. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027 or one day before the next annual stockholders’ meeting, subject to continued service. Each RSU converts into one share of common stock at vesting. He was also granted stock options for 263,884 shares at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning on July 18, 2026, and expiring on June 18, 2036. Following these awards, he directly holds 344,456 shares of common stock and 263,884 stock options.
Mackay Sean reported acquisition or exercise transactions in this Form 4 filing.
STANDARD BIOTOOLS INC. reported that SVP & Chief Business Officer Sean Mackay received a grant of 500,000 shares of Common Stock in the form of restricted stock units. These RSUs were granted at no cash cost and increase his direct holdings to 1,506,552 shares after the award.
The RSUs vest over time based on continued service: 40% will vest on June 20, 2027 and the remaining 60% will vest on June 20, 2028, so Mackay receives the underlying shares only if he remains with the company through those dates.
STANDARD BIOTOOLS INC. director Frank Witney reported new equity awards that increase his stake in the company. On June 18, 2026, he received 99,116 Restricted Stock Units (RSUs) and a stock option for 175,923 shares with an exercise price of $0.8297 per share.
The RSUs vest in full on the earlier of June 18, 2027 or one day before the next annual stockholder meeting, subject to continued service. The option vests in twelve equal monthly installments beginning July 18, 2026 and expires on June 18, 2036. Following these grants, Witney holds 309,978 common shares directly and 4,225 shares indirectly through a revocable trust, in addition to the new option position.
STANDARD BIOTOOLS INC. director and 10% owner Eli Casdin reported new equity awards and updated holdings in Form 4. He received 99,116 Restricted Stock Units that vest in full on the earlier of June 18, 2027 and one day before the company’s next annual stockholder meeting, with each RSU delivering one share of common stock upon vesting.
Casdin was also granted stock options for 175,923 shares of common stock at an exercise price of $0.8297 per share, expiring on June 18, 2036 and becoming exercisable in twelve equal monthly installments starting July 18, 2026. Following these awards, he holds 3,053,169 shares directly and has additional indirect holdings of 72,100,000 shares through Casdin Partners Master Fund, L.P., 2,744,219 shares through Casdin Private Growth Equity Fund, L.P., and 13,939,637 shares through Casdin Private Growth Equity Fund II, L.P.
STANDARD BIOTOOLS INC. director Troy Cox reported equity awards consisting of restricted stock units and stock options as part of his compensation. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027, or one day before the company’s next annual stockholder meeting, subject to continued service. He also received stock options covering 175,923 shares of common stock at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning July 18, 2026, and expiring on June 18, 2036. Following these awards, he directly holds 475,702 shares of common stock.